Eye disease

Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options

Retrieved on: 
Friday, April 19, 2024

You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes?

Key Points: 
  • You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes?
  • In Canada, diabetes affects approximately 10 per cent of the general population.

Locks and keys

  • Every cell in the body needs sugar as an energy source, but too much sugar can be toxic to cells.
  • This equilibrium needs to be tightly controlled and is regulated by a lock and key system.
  • Cells cover themselves with locks that respond perfectly to insulin keys to facilitate the entry of sugar into cells.
  • The body can encounter difficulties producing an adequate number of insulin keys, and/or the locks can become stubborn and unresponsive to insulin.

Severe insulin-deficient diabetes: We’re missing keys!

  • In the severe insulin-deficient diabetes (SIDD) subtype, the key factories — the beta cells — are on strike.
  • Why the beta cells go on strike remains largely unknown, but since there is an insulin deficiency, treatment often involves insulin injections.

Severe insulin-resistant diabetes: But it’s always locked!

  • In the severe insulin-resistant diabetes (SIRD) subtype, the locks are overstimulated and start ignoring the keys.
  • There are many treatment avenues for these patients but no consensus about the optimal approach; patients often require high doses of insulin.

Mild obesity-related diabetes: The locks are sticky!

  • Mild obesity-related (MOD) diabetes represents a nuanced aspect of Type 2 diabetes, often observed in individuals with higher body weight.
  • The locks are “sticky,” so it is challenging for the key to click in place and open the lock.

Mild age-related diabetes: I’m tired of controlling blood sugar!


Mild age-related diabetes (MARD) happens more often in older people and typically starts later in life. With time, the key factory is not as productive, and the locks become stubborn. People with MARD find it tricky to manage their blood sugar, but it usually doesn’t lead to severe complications. Among the different subtypes of diabetes, MARD is the most common.

Unique locks, varied keys

  • In Canada, unique cases of Type 2 diabetes were identified in Indigenous children from Northern Manitoba and Northwestern Ontario by Dr. Heather Dean and colleagues in the 1980s and 90s.
  • Read more:
    Indigenous community research partnerships can help address health inequities

    Childhood-onset Type 2 diabetes is on the rise across Canada, but disproportionately affects Indigenous youth.

  • Acknowledging this distinct subtype of Type 2 diabetes in First Nations communities has led to the implementation of a community-based health action plan aimed at addressing the unique challenges faced by Indigenous Peoples.

A mosaic of conditions

  • Type 2 diabetes is not uniform; it’s a mosaic of conditions, each with its own characteristics.
  • Since diabetes presents so uniquely in every patient, even categorizing into subtypes does not guarantee how the disease will evolve.


Lili Grieco-St-Pierre receives funding from Fonds de recherche du Québec - Santé (FRQS). Jennifer Bruin receives funding from the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC), JDRF, Diabetes Canada.

Prevent Blindness Provides Free Resources as Part of April's Women's Eye Health and Safety Month to Educate Women on Necessary Steps to Help Save Sight

Retrieved on: 
Wednesday, March 27, 2024

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month. According to Orbis International, globally there are 112 million more women than men living with vision loss, including blindness. Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.

Key Points: 
  • CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month.
  • Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.
  • Women have a higher prevalence of age-related macular degeneration, cataract, dry eye, glaucoma, refractive error and thyroid eye disease.
  • For more information on women's eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org.

Ophthalmology innovations paving the way for diagnosis & treatment of age-related macular degeneration (AMD)

Retrieved on: 
Wednesday, February 7, 2024

TORONTO, Feb. 7, 2024 /CNW/ - Age-related macular degeneration (AMD) is one of the leading causes of vision loss for people over the age of 55 and today, affecting approximately 2.5 million Canadians.

Key Points: 
  • TORONTO, Feb. 7, 2024 /CNW/ - Age-related macular degeneration (AMD) is one of the leading causes of vision loss for people over the age of 55 and today, affecting approximately 2.5 million Canadians.
  • As February marks AMD Awareness Month, the Canadian Ophthalmological Society (COS) is educating Canadians about the importance of early diagnosis and treatment, along with vision care innovations that will play a key role in slowing down the progression of this eye disease.
  • AMD is a degenerative disease that happens when part of the retina called the macula is damaged.
  • To learn more about AMD, its risk factors, diagnosis and treatment visit www.see the possibilities.ca .

Located in Seoul, Korea, Topcon Korea Medical Co., Ltd. (TKM) Was Established and Formally Launched in 2023.

Retrieved on: 
Friday, February 2, 2024

Topcon Corporation (HQ: Itabashi-ku, Tokyo; President: Takashi Eto) (henceforth Topcon Healthcare) has established Topcon Korea Medical Co., Ltd. (HQ: Seoul, South Korea, President: Artur Chu) (henceforth TKM) to strengthen and expand its eyecare business in South Korea.

Key Points: 
  • Topcon Corporation (HQ: Itabashi-ku, Tokyo; President: Takashi Eto) (henceforth Topcon Healthcare) has established Topcon Korea Medical Co., Ltd. (HQ: Seoul, South Korea, President: Artur Chu) (henceforth TKM) to strengthen and expand its eyecare business in South Korea.
  • In South Korea, as in other developed countries, the government is responding to the increase in eye disease associated with an aging population.
  • "Introducing Topcon Korea Medical Co., Ltd., empowering excellence in the Korean market.
  • With a firm foundation built on understanding the needs of our customers in Korea, TKM is poised to revolutionize the industry landscape.

Visgenx and Charles River Announce Expansion of Gene Therapy Manufacturing Alliance

Retrieved on: 
Thursday, December 7, 2023

SAN DIEGO, Dec. 7, 2023 /PRNewswire/ -- Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, announced an extension of their contract development and manufacturing organization (CDMO) collaboration with Charles River Laboratories International, Inc., for VGX-0111, a gene therapy being developed by Visgenx for dry age-related macular degeneration (AMD).

Key Points: 
  • SAN DIEGO, Dec. 7, 2023 /PRNewswire/ -- Visgenx, Inc ., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, announced an extension of their contract development and manufacturing organization (CDMO) collaboration with Charles River Laboratories International, Inc., for VGX-0111, a gene therapy being developed by Visgenx for dry age-related macular degeneration (AMD).
  • "Manufacturing of gene therapies is highly complex and product quality is of paramount importance," said William Pedranti, CEO, Visgenx.
  • "We have the utmost confidence in Charles River to manufacture for VGX-0111 as we work toward our goal to bring treatment for those suffering from dry-AMD."
  • "We are excited to expand our partnership with Visgenx on this gene therapy," said Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions, Charles River.

EyeCheq Bolsters its Executive Team Ahead of Launch

Retrieved on: 
Thursday, November 2, 2023

EyeCheq, an innovator in eye care with its autonomous eye screening platform, announces  Leadership Team expansion.

Key Points: 
  • EyeCheq, an innovator in eye care with its autonomous eye screening platform, announces  Leadership Team expansion.
  • Dr. Silva brings a wealth of expertise in ophthalmology and technological innovation to EyeCheq.
  • Dr. Ali Khoshnevis, EyeCheq CSO, noted "Dr. Silva's arrival promises to be a pivotal step in our journey towards groundbreaking healthcare solutions.
  • I am excited to join the EyeCheq leadership team and to have the opportunity to contribute to the company's growth focused on preventing eye disease and blindness."

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Retrieved on: 
Monday, October 2, 2023

“Jill and Mark’s appointments come at an important time in Aura’s evolution as a late stage clinical development company,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.

Key Points: 
  • “Jill and Mark’s appointments come at an important time in Aura’s evolution as a late stage clinical development company,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
  • “We have built our leadership team with experienced industry leaders who have proven track records of success with multiple drug approvals.
  • Dr. Hopkins is board certified in Ophthalmology from the American Board of Ophthalmology and the Royal College of Surgeons Canada.
  • Before joining Sanofi Genzyme, Dr. Plavsic held various technical leadership positions with AstraZeneca, Q-One Biotech, and Life Technologies.

AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer

Retrieved on: 
Thursday, September 28, 2023

AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointment of Charlotte Arnold as Chief Corporate Affairs Officer.

Key Points: 
  • AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointment of Charlotte Arnold as Chief Corporate Affairs Officer.
  • “Charlotte is a highly regarded corporate affairs executive with extensive background in oncology, who has built and led multiple corporate affairs functions at both private and public biotech companies,” said Jerry Wang, PhD, Chief Executive Officer.
  • “We are excited to welcome Charlotte to AnHeart’s leadership team as we continue to advance towards commercialization.”
    Prior to joining AnHeart, Charlotte served as Senior Vice President, Corporate Affairs at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on eye disease, acquired by Novartis.
  • “I’m very excited about AnHeart’s investigational therapies, which have the potential to make a real impact for people facing certain incurable cancers,” said Charlotte Arnold, Chief Corporate Affairs Officer.

David Huang, M.D., Ph.D., receives Lasker Award for transformative imaging technology

Retrieved on: 
Thursday, September 21, 2023

PORTLAND, Ore., Sept. 21, 2023 /PRNewswire/ -- The United States' most distinguished biomedical research award is being given to Oregon Health & Science University physician-scientist David Huang, M.D., Ph.D., for co-inventing an imaging technology that routinely helps prevent blindness and is increasingly used to diagnose and treat conditions of the heart, brain, skin and more.

Key Points: 
  • Huang is receiving the 2023 Lasker-DeBakey Clinical Medical Research Award as a co-inventor of optical coherence tomography, or OCT, the Albert and Mary Lasker Foundation has announced .
  • "I am proud that millions of people have benefited from a technology that I helped invent three decades ago."
  • Lasker prizes are sometimes referred to as "America's Nobels," as 95 Lasker award winners have gone on to receive the Nobel Prize.
  • Huang shares this year's Lasker-DeBakey award with fellow OCT co-inventors James G. Fujimoto, Ph.D., and Eric A. Swanson, M.S., both of the Massachusetts Institute of Technology.

M&S Technologies Improves Active Eye Tracking with SMARTracker™ 2

Retrieved on: 
Thursday, August 3, 2023

NILES, Ill., Aug. 3, 2023 /PRNewswire-PRWeb/ -- M&S Technologies, makers of a line of visual testing equipment and software, today announced the release of an improved software feature for their Smart System Virtual Reality (VR) headset that better helps maintain patient fixation during visual field testing.

Key Points: 
  • The new SMARTracker™ 2 technology uses a new generation of sophisticated eye tracking capabilities to register when patients have lost fixation on a central point or cross.
  • SMARTracker™ 2 is M&S Technologies' next generation of eye tracking technology.
  • Improving on an already advanced software, it can detect finer eye movements to increase test validity even further, making it the most advanced eye tracking software in the market.
  • Unlike most available headsets on the market, the eye tracking software in the Smart System VR Headset surpasses the competition by detecting even the most subtle eye movements.